Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis

Cystic Fibrosis Clinical Trial

Official title:

Changes in Postprandial Hormone Levels in Cystic Fibrosis Related Diabetes.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06163482
• Other study ID #: 2022-0593
• Status: Recruiting
• Start date: March 28, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: June 2024
• Source: University of Cincinnati
• Contact: Jason Winnick, PhD
• Phone: 513-558-4437
• Email: jason.winnick[@]uc.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this exploratory study, the hormonal responses to a mixed meal will be examined in people with cystic fibrosis. The aim of this study is to find correlates with impaired glucose tolerance that is associated with this population.

Description:

The pancreas plays a key role in the regulation of whole-body glucose metabolism in humans. It contains 1 to 3 million islets, each of which contains several types of endocrine cells including insulin-secreting beta cells, glucagon-secreting alpha cells, and somatostatin- secreting delta cells. Insulin is released in response to a rise in blood glucose after a meal, and promotes glucose utilization by peripheral tissues (e.g., skeletal muscle), which allows the return of blood glucose to a fasting level. Glucagon is released when blood glucose falls below a normal fasting level (~80-100 mg/dL) and it acts on the liver in opposition to insulin, enhancing hepatic glucose production. Somatostatin's role in whole body glucose homeostasis is somewhat more complex. The role it plays in acutely regulating whole-body glucose homeostasis is small in healthy humans. On the other hand, it is capable of inhibiting the secretion of both insulin and glucagon, regardless of ambient metabolic conditions. In addition to its ability to regulate hormone secretion, somatostatin is also known to reduce glucose absorption from the gastrointestinal tract.

CF is the most common life-limiting genetic disease in Caucasians. It is caused by recessive mutations in the gene encoding CF transmembrane conductance regulator (CFTR). The primary pathologic change is secretion of thick ductular mucus, which leads to progressive obstructive damage to the lungs and exocrine pancreas. Damage to the exocrine pancreas, which is responsible for the secretion of digestive enzymes, leads to exocrine pancreas insufficiency (PI) manifested as diarrhea and malabsorption of ingested nutrients, requiring pancreatic enzyme replacement. Pathological changes of exocrine PI occur as early as the first few months of life, and most CF patients are diagnosed with PI before they reach adulthood.

The degree of exocrine PI correlates with risk of developing cystic fibrosis related diabetes (CFRD). However, not all CF patients with PI have diabetes. Patients with CFRD have impaired pancreatic beta cell function which is characterized most prominently by a loss of insulin secretion in response to the ingestion of glucose. Furthermore, it has been reported that glucagon responses to insulin induced hypoglycemia are reduced in CFRD, thereby providing evidence that pancreatic alpha cell function is also impaired in CFRD. One hypothesis for impaired endocrine function in CFRD is a reduction in islet count and/or altered islet-structure. These changes, which are hallmark characteristics of CF, are thought to be preceded by obstructive damage to the exocrine pancreas by thick, viscous pancreatic secretions that result in progressive fibrosis and fatty infiltration of the pancreas. Indeed, immunohistochemical studies of islets from patients with CFRD show significantly reduced insulin-producing cells compared to those of CF patients without diabetes and controls.

It is clear that metabolic regulation becomes progressively worse as the CF phenotype progresses from mild to severe (from exocrine pancreatic sufficiency, to exocrine pancreatic insufficiency, to diabetes). However, the mechanism through which this worsening of metabolic regulation occurs is unclear. In fact, it is possible that in addition to changes in islet morphology, another important factor that could lead to deteriorating metabolic regulation in CF is the mucosal secretions that result in fibrosis and fat infiltration in the pancreas. The aim of the current study is to examine how hormone responses to a mixed meal differ between healthy controls and people with cystic fibrosis, and how these changes correlate with deteriorating glucose tolerance.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 61
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Diagnosed with cystic fibrosis

• Aged 18 to 45 years

• Males and females of any race and ethnicity

• Receiving highly effective CFTR modular therapy

Exclusion Criteria:

• Transplant recipient

• Acute lung function decline or exacerbation within the last 3 months

• Use of systemic glucocorticoids

• Pregnancy

• Known liver disease that would be expected to significantly impact metabolic variable as interpreted by a study doctor

• The presence of any other disease or condition, as interpreted by any one of the study doctors, that would be expected to confound the responses to liquid mixed meal or make participation in the study dangerous to the individual

• People who are cognitively impaired

• People who do not speak English

• For CFRD patients, a daily insulin requirement that exceeds 0.8 U/kg/day

• Any prior history of diabetic ketoacidosis.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Other:
• Mixed meal
Each individual will ingest 5 mL/kg of Boost energy drink.

Locations

Country	Name	City	State
United States	University of Cincinnati	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
University of Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of Insulin	human plasma	Up to 3 hours
Primary	Concentration of Glucagon	human plasma	Up to 3 hours
Primary	Concentration of Somatostatin	human plasma	Up to 3 hours
Primary	Concentration of Glucose	human plasma	Up to 3 hours
Secondary	Concentration of GLP-1	human plasma	Up to 3 hours
Secondary	Concentration of GIP	human plasma	Up to 3 hours
Secondary	Concentration of fatty acids	human plasma	Up to 3 hours